Running Title: SRC-1 mediates repressive DNA methylation in breast cancer 15 Key words: breast cancer, DNA methylation, SRC-1, endocrine resistant breast cancer, hormone-16 dependent cancer, estrogen receptor, metastasis Abstract 1 Purpose: Despite the clinical utility of endocrine therapies for estrogen receptor positive 2 (ER) breast cancer, up to 40% of patients eventually develop resistance, leading to disease 3 progression. The molecular determinants that drive this adaptation to treatment remain 4 poorly understood. Methylome aberrations drive cancer growth yet the functional role and 5 mechanism of these epimutations in drug resistance are poorly elucidated. 6 Experimental design: Genome-wide multi-omics sequencing approach identified a 7 differentially methylated hub of pro-differentiation genes in endocrine resistant breast 8 cancer patients and cell models. Clinical relevance of the functionally validated methyl-9 targets was assessed in a cohort of endocrine treated human breast cancers and patient-10 derived ex vivo metastatic tumours. 11 Results: Enhanced global hypermethylation was observed in endocrine treatment resistant 12 cells and patient metastasis relative to sensitive parent cells and matched primary breast 13 tumor respectively. Using paired methylation and transcriptional profiles we found that SRC-14 1-dependent alterations in endocrine resistance lead to aberrant hyper-methylation which 15 resulted in reduced expression of a set of differentiation genes. Analysis of ER positive 16 endocrine treated human breast tumors (n=669) demonstrated that low expression of this 17
1
Translational Relevance 1 Aberrant DNA methylation-mediated gene silencing frequently occurs in cancer. While 2 substantial effort has been devoted to the elucidation of methylome changes associated 3 with the development of breast cancer, comparatively little is known about the methylome 4 alterations that accompany treatment resistance and their contribution to the metastatic 5 phenotype. In this study we addressed this gap by generating a comprehensive epigenomic 6 map of endocrine treatment resistance and identified a key potentiator, its effectors and 7 their mechanistic and functional output. From this study, we established a methylation 8 molecular marker set of 5 genes whose silencing mediated tumor aggressiveness. 9 Subsequently these markers were confirmed to predict metastatic survival from a cohort of Breast cancer (BC) develops through the accumulation of genetic and epigenetic 2 abnormalities to chief regulators of cell proliferation, differentiation and apoptosis. 3 Estrogen receptor (ER) is a key driver of hormone-dependent BC and its expression is 4 indicative of good prognosis. Despite the efficacy of endocrine treatment, including 5 tamoxifen and aromatase inhibitors (AIs) in ER-positive BC, acquired therapy resistance is 6 common and it remains a major clinical challenge (1). Mechanisms underlying this resistance 7 are complex, highly adaptive and heterogeneous and can vary from patient to patient, from 8 primary to metastatic tissue and even amongst different endocrine treatments. Recent 9 studies of metastatic tissues from patients that have failed AIs revealed a number of 10 mutations, including those activating ESR1 (2), as a feature of resistance. On the other hand, 11 loss of ER function/expression can be found in 20% of metastatic tumors highlighting the 12 dynamic nature of therapeutic resistance (3, 4) . 13 Endocrine treatment-resistant cancer cells activate pathways co-operating and 14 interacting with ER, its co-regulators and transcription factors providing survival advantage 15 and therapeutic escape. One such ER regulator, SRC-1, has been shown to be central to the 16 ability of ER tumors to adapt and facilitate metastatic disease progression (5, 6) . Typically, 17 SRC-1 binds to and co-activates nuclear receptors such as ER to regulate a network of 18 proliferation-and differentiation-associated genes critical to BC progression (7) . Notably, 19 aberrant up-regulation of SRC-1 has been implicated in the development of endocrine 20 treatment resistance in BC, where high protein levels correlate with endocrine resistance 21 and poor clinical outcome (8) (9) (10) . Modulations of these endocrine resistant pathways can be 22 driven by genomic, epigenetic or tumor microenvironment influences. 23 Although current emphasis for tumor profiling is on mutation-level alterations, these 24 approaches have failed to uncover the molecular determinants that drive adaptation to 25 treatment. Conversely, transcriptional and epigenetic reprograming develops with higher 26 frequency and has been observed to functionally affect oncogenes and related signalling 27 pathways (11) (12) (13) . Increasing evidence suggests that aberrant DNA methylation of tumor 28 suppressors and differentiation/developmental genes may represent a major mechanism 29 underlying tumor progression (11) . The discovery of hypo and hyper-methylation (14-16) in 30 4 cancer has led to major advancements towards uncovering novel epigenetic drivers in 1 tumor initiation and progression. Aberrant DNA hypermethylation is the most prominent 2 epi-alteration reported in cancer, originating in regions marked with repressive histone 3 marks (e.g. H3K27me3) (17) ,guided by DNA-methyl transferases (DNMTs) (18) and carefully 4 regulated by transcriptional influencers such as polycomb-repressive complexes (PRCs) 5 (17, 19) and methyl-CpG-binding domain proteins (MBDs) (20-23). These methylome 6 changes are potentially reversible making them prime candidates as novel targets for 7 diagnosis and treatment strategies. Indeed, altered DNA methylation events in BC have 8 been used to identify potential biomarkers (24, 25) , whilst DNA methylation signatures can 9 be used to classify tumor subtypes (26) (27) (28) or inform endocrine response (29, 30) . Although, 10 several studies have reported shifts in the epigenetic profile of endocrine resistant cell line 11 models (29, 31, 32) , the role of epigenetic dysregulation in endocrine treatment resistance is 12 still poorly understood, as are the key potentiators of its function. 13 In the current study, we have investigated the methylome profile of endocrine 14 resistant tumors and we report on extensive global epigenomic remodeling events unique 15 to treatment resistant disease. Our investigation places SRC-1 in a critical position in 16 controlling the methylation reprograming in endocrine treatment resistant models and 17 identifies it as a necessary component in the core regulatory circuitry. SRC-1's role as a 18 transcriptional repressor was further validated as SRC-1-dependent events mediate 19 aberrant methylation leading to reduced expression of a set of differentiation genes. We 20 demonstrate that SRC-1 is pivotal in recruiting the co-repressor complex to a hub of pro-21 differentiation genes, thus remodeling BC cells to promote a more aggressive endocrine 22 treatment resistant phenotype. Our data support a model where epigenetic reprograming 23 towards a poorly differentiated cell profile, driven by an oncogenic co-regulator, is a crucial 24 step in endocrine treatment resistance.
26

Methods
27
Cell culture 28 The endocrine sensitive MCF7 cells (ATCC, USA) were cultured in Minimum Essential 29 Medium Eagle (MEM) (M2279, Sigma) supplemented with 10 % fetal calf serum (FCS) 30 5 (F7524, Sigma). The endocrine resistant LY2 breast cancer cells were a gift from Robert 1 Clarke (Georgetown, USA) and were cultured as previously described (33). Each cell line was 2 tested for mycoplasma (LT07-118, Lonza), genotyped (SourceBioScience) and authenticated 3 according to ATCC guidelines. The T347x brain metastatic primary cell line was derived from 4 an ER+ PR-HER2+ patient tumor, which was expanded in NOD-SCID mice (34). The tumor 5 was resected, dissociated and cultured in human breast epithelial cell (HBEC) media as 6 described previously (34) for in-vitro experiments. 7 CRISPR/Cas9, Lentiviral transduction, siRNA transfection 8 The LY2 SRC-1 knockout (KO) cell line was created using CRISPR/CCas9 technology (Santa 9 Cruz) details of the transfection procedure are provided in supplementary information. The 10 LY2 luciferase (LY2-Luc), LY2 shSRC-1 KD (knockdown) and LY2 shNT (non-targeting) cells 11 were created by transducing LY2 cells with viral particles as previously described (35). Gene 12 silencing was carried out using predesigned siRNAs directed against NTRK2 (144201, 13 Ambion), non-targeting siRNA control (NT siRNA) (AM4611, Ambion), NR2F2 (J-003422-06-14 0002), CTDP1 (J-009326-080002), SETBP1 (J-013930-18-0002), POU3F2 (J-020029-06-0002) 15 and NT siRNA (J.Human-xx-002) (Dharmacon, USA) and transfection was carried out using 16 Lipofectamine 2000 Fluorescence-activated cell sorting (FACS) was performed on the FACS ARIA II (BD 29 Biosciences). The LY2 CRISPR/Cas9 cells (clone 7c and 9c) were sorted for both CRISPR HDR 30 plasmid (Red Florescent Protein) and luciferase (Green Florescent Protein). Stem cell 6 analysis was carried out on the BD FACS Canto II (BD Biosciences). Cell lines which 1 underwent gene silencing were analyzed by flow cytometry 48 hrs post siRNA transfection 2 for with NTRK2, NR2F2, CTDP1, SETBP1, and POU3F2. Cells were stained with CD24 3 (555428; BD Biosciences), CD44 (555478; BD Biosciences), 4 Thermofisher) and CD49f (17-0495-82, Thermofisher) antibodies. Data were analyzed using 5 FlowJo Software (FlowJo, USA).
6
Mammosphere forming, anchorage independence, 3D acini and motility assays 7 Functional assays were performed in the LY2 luc control cell line, LY2 SRC-1 CRISPR/Cas9 KO 8 cells (clones 7c and 9c), and LY2 shSRC-1 cells 24 hrs post gene silencing with NTRK2, NR2F2, 9 CTDP1, SETBP1, POU3F2. All functional assays were carried out with cells treated with 4-10 OHT [10 -7 M].
11
Mammosphere culture and analysis was performed as previously described. 12 Anchorage independence was analyzed using the agarose colony formation assay as 13 previously described (36). 14 3D Acini assays were performed to assess cellular polarization/organization. Cells were 15 cultured for 21 days, then fixed and stained as previously described (8). 16 Cell migration was carried out using the Cellomics Cell Motility Kit (K0800011, Thermo 17 Scientific) as previously described (8).
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Chromatin Immuno-precipitation (ChIP) 19 ChIP was performed on the LY2 cells, LY2-luc and LY2 CRISPR/Cas9 SRC-1 KO cell line (clone 20 7c) as previously described (4). Full details can be found in Supplementary Methods. 
Results
27
SRC-1 global gene methylation signature in endocrine resistant breast cancer. 28 Perturbations in DNA methylation profiles may influence tumor initiation, metastatic 29 progression and resistance to treatment. To investigate global aberrant DNA methylation as 9 a function of treatment resistant BC we undertook targeted bisulfite sequencing in 1 endocrine sensitive and resistant samples. Density distribution of events examining 2 differential methylation revealed increased hypermethylation in endocrine resistant cells 3 and an ER+ve metastatic patient tumor, relative to parent sensitive cells and matched 4 primary tumor tissue, respectively ( Fig. 1a ). Moreover genome wide CpG methylation was 5 observed in the metastatic tumor in comparison to the matched primary tissue (Fig 1a) . 6 Having established the role of differential DNA methylation in acquired resistance the 7 resulting changes to ER binding was examined as differential ER-binding is observed in 8 tumors from patients with poor outcome (40). ER occupancy of CpG islands in endocrine 9 resistant LY2 cells is greater than in the endocrine sensitive MCF7 cells. Furthermore, 10 tamoxifen driven ER/SRC-1 co-occupancy at these sites suggests a role for the steroid 11 receptor/coactivator complex in mediating these enhanced DNA-hypermethylation events 12 (Fig 1b) . This further supports the role of SRC-1 in transcriptional silencing (35). To 13 understand the contribution of SRC-1 to global methylation, comprehensive genome-wide 14 MeDIP-seq was undertaken in the presence and absence of SRC-1 (shNT and shSRC-1; Fig.   15 S1a) in endocrine resistant cells. Consistent with its role as a coactivator protein, 16 hypermethylation was enriched in the absence of SRC-1 (Fig. 1c,) . However, SRC-1 17 dependent hypermethylation events were also observed throughout the genome (Fig. 1c ).
18
Of interest, from SRC-1-ChIP-seq analysis in endocrine resistant cells (38) we observed an 19 over-representation of methyl marks at CpG islands within 2Kb of an SRC-1 peak ( Fig. 1d ). 20 The initial methylome data suggests that SRC-1-dependent events result in an 21 altered methlyome profile and may in fact suppress specific gene sets in the resistant 22 setting. Before attempting to dissect the underlying mechanism it was important to 23 determine the identity of these suppressed genes and if such genes were likely to contribute 24 to the resistant state. RNA-seq identified 736 genes down-regulated in the presence of SRC-25 1 (Fig. 1e ). Correspondence analysis and heatmap displayed separation between shNT and 26 shSRC-1 gene expression ( Fig. S1 .b,c). Pathway analysis of the SRC-1 suppressed genes 27 revealed a preponderance of genes pertinent to cell development and pro-differentiation 28 ( Fig. S2 ). This is particularly poignant since a significant function of DNA methylation is in 29 modulating differentiation and developmental pathways. We integrated data from the SRC-30 1-RNA-seq, ChIP-seq and MeDIP-seq assays to identify putative genes that were directly 10 suppressed by SRC-1-dependent DNA methylation ( Fig. 1f , Table 1 ). From these 9 genes 1 NTRK2, NR2F2, CTDP1, SETBP1 and POU3F2 have described roles in cellular development 2 and differentiation. ChIP and qPCR analysis confirmed these genes as direct SRC-1 targets 3 ( Fig. S3a, b ). 4 Functional role of SRC-1 in disease progression in endocrine resistance is mirrored by the 5 roles of NTRK2, NR2F2, CTDP1, SETBP1 and POU3F2 in tumor suppression. In endocrine 6 treatment resistant cells SRC-1 is a known mediator of drug resistance phenotype (36, 38) . 7 Loss of SRC-1 expression can lead to re-sensitization of endocrine resistant cell lines to 8 tamoxifen treatment (Fig S4a,b) .To assess the impact of SRC-1 and its suppressed pro-9 differentiation target genes on tumor progression we investigated the role of the was used in LY2 shSRC-1 cells to transiently silence the SRC-1 pro-differentiation target 22 genes NTRK2, NR2F2, CTDP1, SETBP1 and POU3F2 (Fig. S5b ). Silencing of NTRK2 and 23 POU3F2 significantly reduced the number of CD24 + /44 differentiated cells ( Fig. 2a ). In these 24 endocrine resistant cells, knockout of SRC-1 resulted in reduced self-renewal capacity (2 nd 25 generation mammosphere), colony formation, cell organization and migration ( Fig. 2b-e ). In 26 contrast, silencing of each of the SRC-1 target genes displayed loss of cell differentiation 27 through increased self-renewal capacity and colony formation along with loss of cellular 28 organization ( Fig. 2b-d ). Furthermore, silencing of the pro-differentiation genes elevated 29 migratory capacity of the endocrine resistant breast cancer cells ( Fig. 2e ). NTRK2, NR2F2, CTDP1, SETBP1 and POU3F2 expression in breast cancer patients. The 1 clinical relevance of the SRC-1 pro-differentiation genes was examined in a cohort of breast 2 cancer patients. We used GOBO to analyze transcript expression of the gene set in 3 published clinically annotated primary tumors (39). The genes stratified according to PAM50 4 subtype (p<0.0001) with the highest expression levels observed in luminal A and normal-like 5 tumors ( Fig.3a) . Gene set expression also associated with ER+ve primary breast cancers 6 (p<0.00001) (Fig.3a) . In a cohort of ER+ve tamoxifen treated patients (n=669), ranked sum 7 of SRC-1 suppression genes transcript significantly associated with reduced distant 8 metastatic disease free survival (p=0.00009) (Fig.3b, c) . The association of dysregulated gene 9 set with good outcome strongly aligns with its pro-differentiation role and suggests that its 10 suppression can be detected in a relatively large subset of human BC and could contribute 11 to risk assessment for endocrine treatment resistance. This relationship would appear to be 12 treatment dependent as the reverse relationship was observed in ER+ve untreated patients 13 (n=343) where high transcript expression of the gene set associated with reduced 14 recurrence free survival (p<0.05) ( Fig. 3c, S6 ). 15 To enhance the translational value of our findings and further reinforce the role of 16 aberrant DNA methylation in this dysregulated pathway we employed an ex vivo model of 17 endocrine resistant metastatic tumors to evaluate the effect of DNA methylation disruption 18 ( Fig. 3d ). These models recapitulate tissue heterogeneity, morphology and architecture and 19 create a unique opportunity for drug efficacy studies and pose a good platform for 20 mechanistic studies. Given our findings that SRC-1 target genes were regulated through 21 inappropriate methylation-dependent silencing, we first used a DNA methyltransferase 22 inhibitor, RG108, to confirm its capacity to re-express the SRC-1 target genes in endocrine anti-tumor effect as demonstrated by a significant decrease in proliferating cells (ki67+) 30 compared to vehicle treated tumors ( Fig. 3e and f) .This proof of concept study further supports methylation as a necessary and reversible mechanism promoting tumorigenesis in 1 multiple models of endocrine treatment resistance.
2
SRC-1 in combination with a complex of methylators represses expression of NTRK2,
3 NR2F2, CTDP1, SETBP1 and POU3F2. We wanted to further delineate the mechanistic 4 pathway involved. We interrogated the DNA methylation of the SRC-1 pro-differentiation 5 genes by analyzing methyl sites from Seq Cap Epi data from endocrine resistant LY2 cells 6 and matched primary and metastatic tumor from an endocrine resistant patient. The 7 percentage methylation indicating the proportion of cytosine's methylated at each CpG 8 probe is reported for the LY2 cells and metastatic brain tissue (Fig. 4a ). Differential 9 methylated regions were analyzed from the resistant metastatic tumor and the matched 10 primary. Hypermethylated regions were identified upstream of NTRK2, CTDP1, SETBP1 and 11 POU3F2 and a hypomethylated region upstream of NR2F2 (Fig. 4a ). These regions 12 corresponded to SRC-1 peaks as determined from global ChIP-seq analyses in LY2 cells (Fig.   13 4a). 14 The expression of the maintenance and de novo methyltransferases, DNMT1 and 15 DMMT3a, respectively were found to be reduced in the absence of SRC-1 (LY2 shSRC-1) 16 compared to the control (LY2 shNT) (Fig. 4b) . As DNA and histone lysine methylation 17 systems are highly interrelated and rely mechanistically on each other, we investigated 18 histone methylation at the SRC-1 target genes. Consistent with this, elevated recruitment of 19 the histone repression marker H3K27me3, a known mediator of de novo DNA 20 hypermethylation, to the pro-differentiation genes was observed (Fig. 4c ). 21 Network of nuclear receptors and co-regulator proteins is highly complex, 22 interconnected and regulates many transcriptionally active regions in the cistrome that are 23 co-ordinately occupied by multiple nuclear receptors including ER, PR and AR (41,42). To 24 further dissect the nuclear receptors' contribution to the SRC-1 regulated processes we 25 investigated ER, AR and PR binding to the target genes. Enhanced recruitment of ER and its 26 coactivator protein SRC-1 were observed at each of the pro-differentiation genes (Fig. 4d) . 27 Interestingly, we found an enhanced, but non-significant, recruitment of PR to most of the 28 target genes, but not AR (Fig. 4d, S8a) . Treatment with antagonists against ER and PR 29 produced no reduction in the recruitment of SRC-1 to each of the pro-differentiation genes 13 ( Fig. S8b) . Consistent with the specificity of SRC-1's contribution in this process, no binding 1 of SRC-3 was detected at any of the target genes (Fig. S8c) . 2 To unravel the complex that may regulate methylation at these SRC-1 target genes 3 we examined the recruitment of MBD proteins to the pro-differentiation target genes. MBD 4 proteins bind methylated DNA and are believed to participate in DNA methylation-mediated 5 transcriptional repression (43). DNA binding of MECP2 and MBD2, two MBD family 6 members, to each of the target genes was confirmed by ChIP and additionally with ChIP-re-7 ChIP qPCR indicating co-occupancy (Fig. 4e, f) . To determine if SRC-1 is essential for the 8 recruitment of the methylation regulatory module we examined recruitment of the methyl 9 proteins to the pro-differentiation genes in the absence of SRC-1 using the LY2 SRC-1 10 CRISPR/Cas9 7c KO. Loss of MBD protein-DNA binding at each of the targets was observed in 11 these cells in comparison to the luciferase control endocrine resistant cells (Fig.4g ).
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Moreover, SRC-1-dependent recruitment of the histone deacetylase protein, HDAC2, a 13 known complex partner of the MBD methyl proteins, was also observed in each of the 14 target genes, in which loss of recruitment was again observed after SRC-1 KO (Fig. 4i) . 15 Interestingly, we detected no such consistent significant binding of the methyl complex to 16 target genes in endocrine sensitive MCF7 cells ( Fig. S8d-g Consistent with these studies we observed differential methylation patterns between 6 sensitive and treatment resistant breast cancer cell lines and patient tumors and uncovered 7 extensive hypermethylation and hypomethylation events unique to treatment resistant 8 disease. To date the mechanism of communication between the key transcriptional 9 mechanics of the resistant cell with the methylation process to drive the phenotype and 10 promote disease progression has not been elucidated. We examined the global differential 11 methylation observed between endocrine sensitive and resistant models and patient 12 tumors, defining a role for the ER coregulatory protein SRC-1 in mediating gene repression 13 which is both functional and clinically relevant. an amphipathic role for the ER co-regulator protein SRC-1 has also been described, where 18 SRC-1 the classic steroid receptor coactivator protein, has been shown to transcriptionally 19 repress the differentiation marker CD24 and the apoptotic protein PAWR (35). In this study, 20 employing integrated multi-omics approach, we found specific global SRC-1 dependent 21 hypermethylation, corresponding to regions of transcriptional repression, which were 22 confirmed as direct SRC-1 targets. Though the complex interplay between nuclear receptors 23 and coregulatory proteins is known to play a significant role in the development of breast 24 cancer, data reported here suggest that SRC-1 repression of these target genes is not 25 dependent on multiple nuclear receptor interactions. Importantly, pathway analysis 26 revealed an over representation of these genes in development and differentiation 27 processes, suppression of which are essential for tumor development. 28 In this study we defined five genes with described roles in cellular development and 29 differentiation that are direct suppression targets of SRC-1. Aberrant methylation of these 30 genes in endocrine resistant models and in patient tumors was observed. Increased expression of the maintenance and de novo methyltransferases, DNMT1 and DMMT3a, 1 were seen in the presence of SRC-1. Moreover the presence of the lysine methylator, 2 H3k27me is consistent with the established mechanistic link between DNA-and histone-3 methylation (17) and is indicative of the epigenetic activity at these regions. 4 To elucidate the mechanism of repression and the regulatory link between 5 methylation and the steroid receptor transcriptional system we investigated the methylome 6 pertinent to the target genes. MBD2 and MECP2, members of the methyl binding domain 7 (MBD) protein family which deciphers the DNA methylation code (47), were both found to 8 be recruited to the target genes. Full suppression capacity of the MBD protein complex is 9 dependent however on histone deacetylation (20). Recruitment to the target genes of the 10 histone deacetylator, HDAC2, a known MECP2 binding partner (20), was also observed. The 11 dependence of this regulatory methlyome on SRC-1 provides evidence of the central role of 12 this transcriptional protein in coordinating these epigenetic events. 13 De-repression of the SRC-1 epi-silenced genes influences a number of key functional 14 pathways whose deregulation is a facet of endocrine treatment resistant phenotype. 15 Integration with existing patient datasets and patient survival data (39) revealed that 16 reduced expression of this gene set associated with poor outcome in tamoxifen-treated 17 population. This was not true for treatment naïve populations suggesting that this is a 18 feature of long-term endocrine treatment. Therefore, SRC-1 dependent methylated genes 19 identified here underline key molecular features that distinguish between good outcome 20 and poor outcome in endocrine treated ER+ve patients. Still, these interpretations warrant 21 further clinical investigation in larger independent cohorts as methylation of specific genes 22 have the power to be a valuable tool in the management of breast cancer (48). 23 In contrast to mutational modifications, epigenetic alterations are potentially 24 reversible (49). Demethylating agents have demonstrated therapeutic benefit at low dose 25 long-term treatments in solid tumors (50). However, these agents can have broad impacts 26 on gene expression and also the number of tumor-associated methylated genes could 27 impact its efficacy. To demonstrate methylation as a crucial mechanism of the aggressive 28 phenotype observed in our models, we show that DNA demethylator treatment re-29 expressed SRC-1 suppression genes and significantly inhibited proliferation of ex vivo 16 endocrine resistant metastatic tumors. Promising observations reported here, warrant 1 further studies using a larger cohort of patient tumor samples, providing full clinical 2 relevance of these mechanisms in breast cancer patients. 3 Taken together data presented here link, for the first time, the key transcriptional 4 machinery of the endocrine resistant cell with global methyl-dependent gene suppression. 5 We demonstrate that SRC-1 is one of the key orchestrators of the endocrine resistant 6 methylome which has consequences that are both functionally and clinically relevant. ). (f) The 736 genes down regulated in shNT (from RNA-seq analysis, Table S1 ) were 21 filtered and 251 genes were identified within 5kb upstream of the transcription start site 22 (ChIP-seq analysis, Table S2 ), from 251 genes, nine genes were found with adjacent 
